Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Inclusion Criteria:

1. Subjects who are willing and able to provide Institutional Review Board (IRB)approved written informed consent and privacy language as per national regulations.

2. Men and non-pregnant women, ages 18-75 years inclusive.

3. Female subjects of childbearing potential must agree not to become pregnant duringthe clinical study, have a negative pregnancy test at Screening Visit, and agree toone of the following:

• Use two highly effective forms of birth control starting at initial screeningand continuing throughout the study duration.

• Practice abstinence starting at initial screening and continuing throughout thestudy duration.

4. Subjects with a Myasthenia Gravis Foundation of America Clinical ClassificationClass II-IV.

5. Subjects positive for anti-AChR antibodies by radioimmunoassay (RIA) (LabCorpCentral Laboratory Services Inc.).

6. Subjects with MG-ADL Score ≥6 at Screening and Baseline Visit with ≥50% of the scorederived from non-ocular symptoms.

7. Subjects with QMG Score ≥11 at Screening and Baseline Visit.

8. For subjects on any medication used to treat the symptoms of MG (e.g.Corticosteroids, pyridostigmine), subjects must be on a stable dose for a minimum of 90 days prior to enrollment and must agree not to increase their dose throughout thestudy duration unless reviewed and approved by the medical monitor and the siteinvestigator.

9. Female subjects who agree to not breastfeed starting at initial screening andthroughout the study duration.

10. Female subjects who agree to not donate ova starting at initial screening andthroughout the study duration.

11. Male subjects with a spouse or partner of childbearing potential, who themselves andtheir spouse or partner agree to practice an effective form of birth control asdiscussed with the study doctor or study staff starting at Screening and throughoutthe study duration.

Exclusion Criteria:

1. Subjects with a Myasthenia Gravis Foundation of America Clinical ClassificationClass I or V.

2. Subjects with a history of cerebrovascular accident in the past 12 months.

3. Subjects with MG-ADL Score <6 at Screen or Subjects with MG-ADL Score ≥6 at Screenwith ˂50% of the score derived from non-ocular symptoms.

4. Subjects with QMG Score <11 at Screen.

5. Subjects may enter the study following the washout periods for medications asdescribed below prior to screening and refrain from usage throughout the study:

• Tacrolimus within 6 months

• Azathioprine, cyclosporine, methotrexate, or mycophenolate mofetil within 90days

• Anti-FcRn therapies:

• Cyclic Anti-FcRns (e.g., efgartigimod alfa, rozanolixizumab) within 50 days

• Chronic Anti-FcRns (e.g., nipocalimab) within 80 days;

• C5 complement inhibitor (e.g., eculizumab) within 90 days

• Anti-CD20 (e.g., rituximab) within 6 months;

• Other immunomodulatory drugs will be at the discretion of the medical monitorand study site investigator.

6. Subjects who have used immunoglobulins given SC or IV (SCIg or IVIg) orplasmapheresis/plasma exchange (PE) within 4 weeks before Screening.

7. Subjects who have had thymectomy or any other thymic surgery performed within 12months prior to Screening.

8. Subjects with untreated thymic malignancy, carcinoma, or thymoma.

9. Subjects with a history of untreated tuberculosis, a positive PPD skin test, or apositive QuantiFERON test.

• Subjects with documented evidence of satisfactory TB treatment can be consideredafter review with the medical monitor and documentation of treatment course.

10. Subjects who have received administration of any live vaccine (other than intranasalInfluenza) within 28 days or subunit vaccine within 14 days prior to Screening orare planning to receive any vaccination throughout the study duration.

11. Subjects who have received any COVID-19 vaccine within 14 days prior to Screening.Subjects who have received the first dose of any COVID-19 vaccine may not screen forthe study until 14 days following their last dose of the vaccine if applicable.

12. Subjects with laboratory test results at Screening or prior to study dosing that areoutside the normal limits and considered by the investigator to be clinicallysignificant. Note: Clinically significant laboratory test results at screening thatare related to the condition (MG) are acceptable if all inclusion and no otherexclusion criteria are met.

13. Subjects with positive test results for hepatitis B surface antigen (HbsAg),hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV)antigen/antibody as determined at Screening.

14. Subjects with a history of or currently active immune disorders other than MG (including autoimmune disease) unless the condition, after discussion with themedical monitor and study site investigator, has been deemed to be acceptable forthe subject's participation in this clinical study.

15. Subjects with a history of or current active diseases other than myasthenia gravisrequiring immunosuppressive drugs (including azathioprine, prednisone, prednisolone,budesonide, cyclosporine, tacrolimus, methotrexate, or mycophenolate mofetil) unlessthe condition, after discussion with the medical monitor and site investigator, hasbeen deemed to be acceptable for the subject's participation in this clinical study.

16. Subjects with a clinical history of significant cardiovascular disease as determinedby the Investigator.

17. Subjects with a complication or medical history of malignancy within the past 5years which, in the investigator's opinion, makes the subject unsuitable for studyparticipation.

18. Subjects with a history of mast cell activation disease.

19. Subjects who, in the investigator's opinion, will be unable to adhere to studyprocedures.

20. Subjects who have received an investigational therapy other than CNP-106 within 28days or 5 half-lives, whichever is longer, prior to Screening.

21. Subjects with any known active condition which, in the investigator's opinion, makesthe subject unsuitable for study participation.

22. Known sensitivity to any components of CNP-106 (PLGA, sucrose, mannitol, or sodiumcitrate).